Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASAIt is intended for the maintenance treatment of advanced epithelial ovarian, Fallopian tube and primary peritoneal cancer
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | EMA recommends extension of therapeutic indications for sacituzumab govitecan | 0 | 11.1 | 18-09-2026 |
| 2 | EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan | 0 | 5 | 26-06-2026 |
| 3 | EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin | 0 | 5 | 19-06-2026 |
| 4 | Enhertu превзошел стандартную первую линию терапии при HER2-мутантном раке легкого в исследовании III фазы | 0 | 17.14 | 18-08-2026 |
| 5 | FDA approves groundbreaking new pancreatic cancer drug | 0 | 7.77 | 26-08-2026 |
| 6 | Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian Cancer | 0 | 9.84 | 01-10-2026 |
| 7 | FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma | 0 | 13.78 | 19-10-2026 |
| 8 | Камизестрант в комбинации с ингибитором CDK4/6 зарегистрирован в ЕС для применения в первой линии терапии распространенного ER-положительного рака молочной железы | 0 | 14.56 | 12-08-2026 |
| 9 | Enzyme USP15 present a promising new target for ovarian cancer treatment | 0 | 8.75 | 25-09-2026 |